Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (731-740 of 755) with videos related to

Pageof 76
Sort By:
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
The Journal of Rheumatology|February 15, 2007
Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi, Janet E Pope, Philip Clements, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaDinesh Khanna, John D Fitzgerald, Puja P Khanna, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritisDinesh Khanna, Puja P Khanna, John D Fitzgerald, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definitionCosimo Bruni, Maya H Buch, Daniel E Furst, et al.
Pageof 76

Showing results (731-740 of 755) with videos related to

Sort By:
Pageof 76
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
The Journal of Rheumatology|February 15, 2007
Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi, Janet E Pope, Philip Clements, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaDinesh Khanna, John D Fitzgerald, Puja P Khanna, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritisDinesh Khanna, Puja P Khanna, John D Fitzgerald, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
The Journal of Rheumatology|October 6, 2005
Minimal disease activity for rheumatoid arthritis: a preliminary definitionGeorge A Wells, Maarten Boers, Beverley Shea, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definitionCosimo Bruni, Maya H Buch, Daniel E Furst, et al.
Pageof 76